# Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC

> **NCT07281716** · PHASE1,PHASE2 · RECRUITING · sponsor: **Dan Feng** · enrollment: 24 (estimated)

## Conditions studied

- Metastatic Microsatellite Stable Colorectal Carcinoma

## Interventions

- **DRUG:** Nadunolimab
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT07281716
- **Lead sponsor:** Dan Feng
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2028-12-15
- **Final completion:** 2028-12-15
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07281716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07281716, "Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07281716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*